Molecular Analysis of Therapy Choice (MATCH): A Phase II Basket Trial to Assess Targeted Therapies


Full Title

EAY131: Molecular Analysis for Therapy Choice (MATCH)(CIRB)


The purpose of this study is to see how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have continued to grow after at least one line of standard treatment, or for which no standard therapy exists. Genetic tests look at the unique genetic material (genes) of patients’ tumor cells. Patients with genetic abnormalities may benefit more from treatment which targets their tumors’ particular genetic abnormalities. Identifying these genetic abnormalities first may help doctors plan more effective treatment for patients with solid tumors, multiple myeloma, or lymphoma.

Patients’ tumors will be genetically analyzed first. Then the researchers will see if it is possible to match each patient with an anticancer drug designed to target the tumor’s genetic abnormalities. Not every patient will have such a match. Some study drugs are taken by mouth, while others are given by vein.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a solid tumor, multiple myeloma, or lymphoma that has continued to grow despite standard therapy or for which no standard therapy exists.
  • At least 4 weeks must pass between the completion of prior treatment and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. David Hyman at 646-888-4544.